Logo

Avalon Closes $70M Series B Round

Dec 17, 2001

NEW YORK, Dec. 17 - Avalon Pharmaceuticals has closed a Series B private equity round worth $70 million that it will use to expand the development of its genomics-based drug-screening approach, the company said on Monday.

 

CDP Sofinov led the round, which also included EuclidSR Partners, AIG Global Investment Group, Hambrecht & Quist Capital Management, MDS Capital, RBC Capital Partners, GeneChem, OrbiMed Advisors, and KBL Healthcare Ventures.  

 

"This marks an important milestone for the company," said Kenneth Carter, CEO of Gaithersburg, Md.-based Avalon. He added that the cash infusion will help the company develop the technology that will "lead to the accelerated identification of innovative small molecule drugs."

Breaking News
The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.